Key result
Intranasal TS+c-di-AMP vaccination cuts chronic cardiac arrhythmias by an absolute ~27% in Chagas models.
Why the study?
Chagas disease causes severe complications such as acute myocarditis and chronic fibrosing cardiomyopathy in 30% of infected individuals, yet no licensed vaccine is currently available to prevent it.
Does prophylactic intranasal vaccination with recombinant trans-sialidase plus c-di-AMP (TS+A) reduce parasite burden and mitigate acute and chronic cardiomyopathy in a murine model of oral Trypanosoma cruzi infection?
Does prophylactic intranasal vaccination with recombinant trans-sialidase plus c-di-AMP (TS+A) reduce parasite burden and mitigate acute and chronic cardiomyopathy in a murine model of oral Trypanosoma cruzi infection?
This preclinical study demonstrates that an intranasal mucosal vaccine combining a recombinant trans-sialidase fragment with c-di-AMP adjuvant elicits mucosal and systemic immunity that attenuates both acute myocarditis and chronic fibrosing cardiomyopathy after oral T. cruzi infection.
Answers are grounded in this paper and cite their sources.
Does not yet change clinical practice for Chagas cardiomyopathy; hypothesis-generating for mucosal TS vaccines pending human trials.
Chagas disease, caused by Trypanosoma cruzi, leads to severe complications in 30% of infected individuals, including acute myocarditis and chronic fibrosing cardiomyopathy. Despite the significant burden of this disease, there is currently no licensed vaccine available to prevent it. This study aimed to evaluate the mucosal and systemic immunogenicity as well as the prophylactic efficacy of a mucosal vaccine candidate and its impact on both acute and chronic cardiomyopathy. The results showed that the nasal administration of trans-sialidase (TS) plus c-di-AMP (TS+A) vaccine elicited a NALT expression of IFN-γ, IL-17a and IL-4 mRNA as well as a nasal-specific production of IgA. An in vivo challenge with TS also triggered increased proliferation of lymphocytes from the NALT, sentinel cervical lymph node, and spleen. TS+A immunization increased the plasma levels of Th1/Th2/Th17 cytokines and elicited an evident cellular response by which to judge enhanced delayed-type hypersensitivity responses following a TS footpad challenge. After oral infection, TS+A-vaccinated mice showed significantly reduced parasitemia and parasite load in the heart, muscles and intestines, while markers of hepatic and muscle damage as well as clinical manifestations of acute infection were strongly diminished. TS+A also attenuated acute myocarditis and the expression of inflammatory markers in the heart. The protection conferred by TS+A extended into the chronic phase, where it resulted in a clear reduction in chronic myocarditis, fibrosis and functional electrocardiographic abnormalities, associated with a decreased expression of the pro-fibrotic TGF-β. These results revealed that it is possible to develop a mucosal vaccine against T. cruzi based on TS and c-di-AMP that is capable of reducing the development of Chagas cardiomyopathy, the hallmark of Chagas disease.
No takes yet. Share an insight, caveat, or question.
Pacini et al. (2024) studied Preclinical oral Chagas disease (Trypanosoma cruzi infection) and Chagas cardiomyopathy. Intranasal N-terminal trans-sialidase (TS) fragment plus c-di-AMP adjuvant (TS+A) vs. Saline solution vehicle (SS group), 10 μg N-terminal TS fragment alone (TS group), or c-di-AMP adjuvant alone (A group) was evaluated on Chronic cardiac arrhythmias on ECG at 111 days post-infection (p=<0.05). Intranasal TS+c-di-AMP vaccination reduced cumulative parasitemia 3-fold and lowered chronic cardiac arrhythmias to -66.6% in controls.
Synapse has enriched 10 related papers. Consider them for comparative context: